Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match
Executive Summary
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
You may also be interested in...
Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Pfizer And Ionis’s Antisense Cholesterol Candidate Sparks Safety Worries
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.
Keeping Track: Regeneron Wins US FDA OK For Evkeeza, New Libtayo Uses; G1 Cosela Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker